top of page
Investments
.jpg){kind=logo}
Traxys is a leading, global and diversified physical trader of base and specialty metals, ferro-alloys and industrial minerals with ~$9bn of revenue, ~450 FTEs, 100 years+ of history and a leading market position in the metals critical to the green energy transition
Industry: Business Services
Status: Current
Investment type: Management buyout
Investment year: 2023
Website: www.traxys.com
Press release: Traxys Group to be Acquired by Traxys Management, Optiver and Investors | Business Wire
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a global biopharmaceutical company that is committed to deliver life-changing therapies. Leaders in complement, the team ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. Apellis is advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases
Industry: Healthcare / Biotech
Status: Current
Investment type: Entrepreneurial venture (Potentia Pharmaceuticals that merged with Apellis in 2014)
Investment year: 2002
Website: www.apellis.com
bottom of page